Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care
about
sameAs
Cardiac toxicity of trastuzumab in elderly patients with breast cancerHER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.Assessment of general characteristics of patients with primary metastatic breast carcinoma: single center experience.The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 geneImmune approaches to the treatment of breast cancer, around the corner?Molecular-targeted nanotherapies in cancer: enabling treatment specificity.Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer.Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
P2860
Q26741182-E09BD9B1-EA8E-4FE8-9C01-907F4D8B4CFBQ35886688-E57DEF1C-11E1-4288-A547-B1548036942BQ36105964-7BEA60D7-02E1-4596-92FF-AE6E7ED0E667Q36917231-E74FF8DC-0643-4ED0-BDB4-7D4C3144170EQ37214212-F7D083C6-78A1-4865-97B9-B211E3C1109DQ37490083-6EA6C002-7596-4A71-BD5B-49DFC2007AFDQ37601851-5014E3E3-9F5C-48CC-828E-8F312AD38D4CQ37605126-5284DE95-F0E3-4D0B-A150-F70534780E49Q37689695-CE96F265-5FCF-465B-86B8-7979DB76F694Q37954497-53BD405A-F18D-4F40-8CC7-930DB23FEE1FQ42050622-BB879A18-55EC-4187-9DBC-6CC7D1092BA7Q47170552-B896D3E0-E84E-421C-BF3D-BE6522F75CF3Q54605374-14846893-1C9D-4B29-9171-3D710A502AE9
P2860
Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Trastuzumab-based therapy for ...... elopment to foundation of care
@ast
Trastuzumab-based therapy for ...... elopment to foundation of care
@en
Trastuzumab-based therapy for ...... elopment to foundation of care
@nl
type
label
Trastuzumab-based therapy for ...... elopment to foundation of care
@ast
Trastuzumab-based therapy for ...... elopment to foundation of care
@en
Trastuzumab-based therapy for ...... elopment to foundation of care
@nl
altLabel
Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer
@en
prefLabel
Trastuzumab-based therapy for ...... elopment to foundation of care
@ast
Trastuzumab-based therapy for ...... elopment to foundation of care
@en
Trastuzumab-based therapy for ...... elopment to foundation of care
@nl
P3181
P1476
Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer
@en
Trastuzumab-based therapy for ...... elopment to foundation of care
@en
P2093
Adam Brufsky
P3181
P356
10.1097/COC.0B013E318191BFB0
P407
P577
2009-08-01T00:00:00Z
2010-04-01T00:00:00Z